• Explore /
  • Poster
  • / An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Interim safety results for fixed-dose durvalumab (D) monotherapy (module A).

An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Interim safety results for fixed-dose durvalumab (D) monotherapy (module A).

Abstract Poster

Authors

Guru P. Sonpavde

Guru Sonpavde

Dana Farber Cancer Institute, Boston, MA

Guru Sonpavde , Cora N. Sternberg , Jae-Lyun Lee , Paulo Andre Palhares de Miranda , Ana Rita Lima , Makan Sarkeshik , Sebastien J. Hotte

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03084471

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 484)

Abstract #

484

Poster Bd #

H7

Abstract Disclosures

Similar Posters

First Author: Guru Sonpavde

First Author: Ronan Joseph Kelly

First Author: Jonathan Wade Goldman

First Author: Jiafu Ji